Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

In 2021, the 30.7 million beneficiaries accounted for over $2 billion in payments for the 101 generic drugs. Under the ...

This article is authored by Dr YK Gupta, president, AIIMS, Jammu and Ankush Kapoor, founder & CEO, Pharma NXT Biotech.

J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...